Growth-suppressive Activity of Raloxifene on Liver Cancer Cells by Targeting IL-6/GP130 Signaling

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 22

PMID 28430601

Citations 7

Authors

Yina Wang

Haiyan Ma

Chongqiang Zhao

Tianshu Liu

Dan Yan

David Jou

Huameng Li

Cuntai Zhang

Jiagao Lu

Chenglong Li

Jiayuh Lin

Sheng Li

Li Lin

Affiliations

Soon will be listed here.

Abstract

Background: Interleukin-6 (IL-6) is a multifunctional cytokine, which is involved in the regulation of differentiation and growth of certain types of tumor cells. Constitutive activation of Signal Transducer and Activator of Transcription 3 (STAT3) induced by IL-6 is frequently detected in liver cancer and has emerged as a viable molecular target for liver cancer treatment. However, few inhibitors targeting up-streams of STAT3 are available for the therapy of liver cancer. We reported the discovery of EVISTA (Raloxifene HCl) as novel inhibitor of IL-6/GP130 protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning. The possible effect of Raloxifene in STAT3 signaling or liver cancer cells is still unclear.

Results: Raloxifene inhibited the P-STAT3 stimulated by IL-6, but not the induction of STAT1 and STAT6 phosphorylation by IFN-γ, IFN-α, and IL-4. Raloxifene inhibited STAT3 phosphorylation and resulted in the induction apoptosis on human liver cancer cell-lines. Raloxifene inhibited the targets of STAT3, such as Bcl-2, Bcl-xl and survivin and cell viability, cell migration, and colony formation in liver cancer cells. Further, daily administration of Raloxifene suppressed the Hep-G2 tumor growth in mice in vivo.

Materials And Methods: The inhibitory effect on STAT3 phosphorylation and activity as well as cell viability, migration, and colony forming ability by Raloxifene was examined in human liver cancer cells. Tumor growth was detected via mouse xenograft tumor mode.

Conclusions: Our results suggest that Raloxifene is a potent IL-6/GP130 inhibitor and may be a chemoprevention agent for liver cancer by targeting persistent STAT3 signaling.

Citing Articles

The gp130/STAT3-endoplasmic reticulum stress axis regulates hepatocyte necroptosis in acute liver injury.

Li X, Wang J, Li Y, He W, Cheng Q, Liu X Croat Med J. 2023; 64(3):149-163.

PMID: 37391912 PMC: 10332293.

Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.

Villarruel-Melquiades F, Mendoza-Garrido M, Garcia-Cuellar C, Sanchez-Perez Y, Perez-Carreon J, Camacho J World J Gastroenterol. 2023; 29(17):2571-2599.

PMID: 37213397 PMC: 10198058. DOI: 10.3748/wjg.v29.i17.2571.

The Combination Sorafenib-raloxifene-loratadine as a Novel Potential Therapeutic Approach Against Human Liver Cancer.

Villarruel-Melquiades F, Hernandez-Gallegos E, Solano-Agama C, Mendoza-Garrido M, Camacho J In Vivo. 2023; 37(3):1156-1163.

PMID: 37103074 PMC: 10188024. DOI: 10.21873/invivo.13190.

Alleviation of Inflammation and Oxidative Stress in Pressure Overload-Induced Cardiac Remodeling and Heart Failure via IL-6/STAT3 Inhibition by Raloxifene.

Huo S, Shi W, Ma H, Yan D, Luo P, Guo J Oxid Med Cell Longev. 2021; 2021:6699054.

PMID: 33824698 PMC: 8007383. DOI: 10.1155/2021/6699054.

Repurposing the selective estrogen receptor modulator to suppress gastrointestinal cancer growth.

Thilakasiri P, Huynh J, Poh A, Tan C, Nero T, Tran K EMBO Mol Med. 2019; 11(4).

PMID: 30885958 PMC: 6460354. DOI: 10.15252/emmm.201809539.

References

Boulanger M, Chow D, Brevnova E, Garcia K . Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003; 300(5628):2101-4. DOI: 10.1126/science.1083901. View

Ihle J . Cytokine receptor signalling. Nature. 1995; 377(6550):591-4. DOI: 10.1038/377591a0. View

Schlessinger K, Levy D . Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res. 2005; 65(13):5828-34. PMC: 2100417. DOI: 10.1158/0008-5472.CAN-05-0317. View

Hayashi M, Rho M, Enomoto A, Fukami A, Kim Y, Kikuchi Y . Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc Natl Acad Sci U S A. 2002; 99(23):14728-33. PMC: 137487. DOI: 10.1073/pnas.232562799. View

Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J . Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J Med Chem. 2014; 57(3):632-41. DOI: 10.1021/jm401144z. View

Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U . Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2006; 109(6):2293-302. DOI: 10.1182/blood-2006-02-003988. View

Aoki Y, Feldman G, Tosato G . Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2002; 101(4):1535-42. DOI: 10.1182/blood-2002-07-2130. View

He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y . Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013; 155(2):384-96. PMC: 4015514. DOI: 10.1016/j.cell.2013.09.031. View

Zhao C, Wang W, Yu W, Jou D, Wang Y, Ma H . A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells. Oncotarget. 2016; 7(11):12917-26. PMC: 4914331. DOI: 10.18632/oncotarget.7338. View

10.

Real P, Sierra A, de Juan A, Segovia J, Lopez-Vega J, Fernandez-Luna J . Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002; 21(50):7611-8. DOI: 10.1038/sj.onc.1206004. View

11.

Bromberg J, Darnell Jr J . The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000; 19(21):2468-73. DOI: 10.1038/sj.onc.1203476. View

12.

STRASSMANN G, Masui Y, Chizzonite R, Fong M . Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J Immunol. 1993; 150(6):2341-5. View

13.

Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C . Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2008; 457(7226):200-4. PMC: 2695248. DOI: 10.1038/nature07475. View

14.

Turkson J, Jove R . STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2001; 19(56):6613-26. DOI: 10.1038/sj.onc.1204086. View

15.

Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K . IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science. 1993; 260(5115):1808-10. DOI: 10.1126/science.8511589. View

16.

Burke W, Jin X, Lin H, Huang M, Liu R, Reynolds R . Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 2001; 20(55):7925-34. DOI: 10.1038/sj.onc.1204990. View

17.

Kaptein A, Paillard V, Saunders M . Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem. 1996; 271(11):5961-4. DOI: 10.1074/jbc.271.11.5961. View

18.

Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S . Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004; 10(1):48-54. DOI: 10.1038/nm976. View

19.

Bowman T, Garcia R, Turkson J, Jove R . STATs in oncogenesis. Oncogene. 2000; 19(21):2474-88. DOI: 10.1038/sj.onc.1203527. View

20.

Liu A, Liu Y, Jin Z, Hu Q, Lin L, Jou D . XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS One. 2012; 7(10):e46624. PMC: 3463519. DOI: 10.1371/journal.pone.0046624. View